Vitiligo, a common depigmenting skin disorder, has an estimated prevalence of 0.5–2% of
the population worldwide. The disease is characterized by the selective loss of melanocytes …

G protein-coupled receptors (GPCRs) are the largest class of receptors in the human
genome and some of the most common drug targets. It is now well established that GPCRs …

The skin serves as a physical barrier and an immunological interface that protects the body
from the external environment,–. Aberrant activation of immune cells can induce common …

Inhibition of Janus kinase (JAK) family enzymes is a popular strategy for treating
inflammatory and autoimmune skin diseases. In the clinic, small molecule JAK inhibitors …

Despite compelling rates of durable clinical responses to programmed cell death-1 (PD-1)
blockade, advances are needed to extend these benefits to resistant tumors. We found that …

Vitiligo is an autoimmune depigment disease results from extensive melanocytes
destruction. The destruction of melanocyte is thought to be of multifactorial causation …

Vitiligo is a multifactorial reversible skin disorder characterized by distinct white patches that
result from melanocyte destruction. Activated CXCR3+ CD8+ T cells promote melanocyte …

Vitiligo is the most common depigmenting disorder affecting 0.1%–2% of the population
worldwide. The characteristic white patches result from the selective loss of melanocytes …

Tissue-resident memory T (Trm) cells form a heterogeneous population that provides
localized protection against pathogens. Here, we identify CD49a as a marker that …

Accumulating data on cellular and molecular pathways help to develop novel therapeutic
strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic …